NIKKEI 225
27,883.78 +365.53 (+1.33%) HANG SENG
20,192.40 +407.75 (+2.06%) CRUDE OIL
72.86 -0.11 (-0.15%) GOLD FUTURES
1,964.30 -2.60 (-0.13%) DOW
32,717.60 +323.35 (+1.00%) BTC-GBP
23,074.46 +903.87 (+4.08%)
Ocugen, Inc. (OCGN)
After hours:
| Previous close | 0.8300 |
| Open | 0.8520 |
| Bid | 0.8785 x 3200 |
| Ask | 0.8920 x 900 |
| Day's range | 0.8400 - 0.8979 |
| 52-week range | 0.8300 - 3.7000 |
| Volume | |
| Avg. volume | 7,000,215 |
| Market cap | 193.146M |
| Beta (5Y monthly) | 3.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2530 |
| Earnings date | 04 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.33 |
- Simply Wall St.
Ocugen, Inc. (NASDAQ:OCGN): Is Breakeven Near?
With the business potentially at an important milestone, we thought we'd take a closer look at Ocugen, Inc.'s...
- Motley Fool
Why Ocugen Stock Eked Out a Win Today
Investors were pleased, if not overwhelmingly so, with Ocugen's (NASDAQ: OCGN) latest set of quarterly results on Tuesday. The biotech published its fourth-quarter and full-year figures that morning, in addition to providing a business update. Ocugen is a clinical-stage biotech that has no revenue at the moment.
- Motley Fool
Ocugen (OCGN) Q4 2022 Earnings Call Transcript
Joining me today are Ocugen's chairman, CEO, and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more detail on our financial results. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties.
